China-based Biotech startup Bota Bio bags $100 million in Series B funding

Headquartered in Zhejiang, China and Lafayette, California, Biotechnology startup Bota Bio raises UD$ 100 million in Series B funding round held today, July 29 2021. Sequoia Capital China led the venture round with existing sponsors Matrix Partners China, Sherpa Healthcare Partners, Source Code Capital and 5Y Capital, said the company in its press release. The latest round led the company to stand on total funding of US$145 million to date. 

Company’s Profile

Bota Bio (also known as Bota Freeway) is a three-year-old global industrial biotechnology company founded by Cheryl Cui. 

The tech startup combines high-standard and digitalised media with lab automation. Bota Bio accelerates the composition and evolution of enzymes or cell-based factories via expanding ahead the design-build-test-learn series to include downstream process development and select non-traditional microbial strains. 

Bota Bio is managed by a skilful team of industry veterans merging data and automation to decode biotechnologies for business and consumer welfare. Visit www.bota.bio for more information.

Fund Utilisation

The brand-new investment will increase the startup’s foreign operations and develop Bota Bio’s lab-to-pilot scale platform to promote the rapid scale-up and recruitment of the company’s product pipeline in consumer goods, nutrition, food and pharmaceutical products.

This venture capital comes after German chemical producer BASF’s BASF investment in March with Bota Bio with an intent to deliver sustainably produced ingredients.

What the CEO has to say

Bota Bio’s co-founder and CEO, Cheryl Cui, remarks in the latest fundraiser, “Most traditional manufacturing comes with a high environmental cost. We are building Bota Bio to innovate solutions that help manufacturers in all industries leverage the power of biology to accelerate the design and scale-up of high-performance products using sustainable processes.” 

She added, “We are empowering a diverse global client base from different industries to develop bio-based alternatives to traditional ingredients. We are thrilled to have this syndicate of renowned investors support our efforts in transforming global manufacturing.”

What the Investors have to say

Neil Shen, founding and managing partner, Sequoia Capital China, said, “Bota Bio is rapidly delivering bio-based and biologically produced products at scale to replace fossil-fuel-based, energy-intensive products and processes with biologically produced sustainable alternatives,” 

He continues, “The Bota Bio team has developed a leading integrated platform to bring innovative and efficient solutions to market for their partners. We are confident that Bota will keep enhancing their ability to accelerate the development of bio-based products, creating more value for consumers while contributing to sustainability on a global scale.”

For more extensive analysis and Market Intelligence reports feel free to approach us or visit our website: Venture Capital Market Intelligence Reports | VCBay.

We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!

Next Article